☰
✕

Hematopoietic stem cell transplantation market

Hematopoietic Stem Cell Transplantation (HSCT) Market, By Transplant Type (Allogeneic, Autologous), By Indication (Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Hodgkin lymphoma (HL), Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Others), By Application (Bone Marrow Transplant (BMT), Peripheral Blood Stem Cells Transplant (PBSCT), Cord Blood Transplant (CBT)), By End User (Hospitals, Specialty Clinics, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Request Free Sample
  • Aug 2023
  • CMI1250
  • 208 Pages
  • Excel & Pdf
  • Biotechnology

The global hematopoietic stem cell transplantation (HSCT) market is estimated to be valued at US$ 2.88 Billion in 2023 and is expected to exhibit a CAGR of 11.2% during the forecast period (2023-2030).

Analysts’ Views on Global Hematopoietic Stem Cell Transplantation (HSCT) Market:

The increasing investment and funding by key market players is expected to drive market growth over the forecast period. For instance, in November 2021, Clade Therapeutics, a biopharmaceutical company focused on discovering and delivering scalable, off-the-shelf, next-generation stem cell-based medicines, announced it had secured an US$87 million in Series A financing led by Syncona Ltd., an investment company. This financing supports the development of the company’s proprietary platform, which enables the immune cloaking of induced pluripotent stem cells (iPSCs) and the differentiation of cloaked stem cells into therapeutic cells. 

Figure 1. Global Hematopoietic Stem Cell Transplantation (HSCT) Market Share (%), By Transplant Type, 2023

Global Hematopoietic Stem Cell Transplantation (HSCT) Market – Drivers

  • Increasing prevalence of cancer: The increasing prevalence of cancer is expected to propel growth of the global hematopoietic stem cell transplantation (HSCT) market over the forecast period. For instance, in February 2022, according to data provided by the World Health Organization, cancer was a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon, rectum, and prostate cancers. The most common in 2020 (in terms of new cases of cancer) were breast (2.26 million cases); lung cancer (2.21 million cases); colon and rectum (1.93 million cases); and prostate (1.41 million cases).
  •  Increasing geriatric population: The increasing geriatric population is expected to drive the global hematopoietic stem cell transplantation (HSCT) market’s  growth over the forecast period. For instance, in October 2022, according to data provided by the World Health Organization, in 2020, Between 2015 and 2050, the proportion of the world's population over 60 will nearly double from 12% to 22%. The share of the population aged 60 years and over will increase from 1 million in 2020 to 1.4 million. By 2050, the world’s population of people aged 60 and older will double (2.1 million). The number of people aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million.

Figure 2. Global Hematopoietic Stem Cell Transplantation (HSCT) Market Share (%), By Region, 2023

Global Hematopoietic Stem Cell Transplantation (HSCT) Market - Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global hematopoietic stem cell transplantation (HSCT) market over the forecast period. North America is estimated to hold 33.5% of the market share in 2023. The global hematopoietic stem cell transplantation (HSCT) market is expected to witness significant growth in the coming years due to increasing inorganic growth strategies such as mergers to expand their product portfolio in North America region. For instance, in May 2021, Jasper Therapeutics, Inc., a U.S. based biotechnology company focused on hematopoietic cell transplant therapies, announced the merger with Amplitude Healthcare Acquisition Corporation, a private life science company, to provide significant capital to accelerate the development of our two innovative programs: Jasper’s first-in-class clinical-stage anti-CD117 antibody transplant conditioning agent and, in parallel, our groundbreaking research stage Engineered Hematopoietic Stem Cell platform.

Global Hematopoietic Stem Cell Transplantation (HSCT) Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, the U.A.E., Egypt, and others, are facing problems with the transportation of things from one place to another.

However, the COVID-19 pandemic had a negative impact on the global hematopoietic stem cell transplantation (HSCT) market, owing to a reduction in bed and operating room capacity, which further led to considerable delays in urgent and semi-elective surgical interventions. According to an American College of Surgeons (ACS) 2021 report, the nature of surgery and anesthesia practices changed during the COVID-19 pandemic as the most elective and non-urgent cases were postponed. 

Global Hematopoietic Stem Cell Transplantation (HSCT) Market Segmentation:

The global hematopoietic stem cell transplantation (HSCT) market report is segmented into transplant type, indication, application, end user and region.

  • Based on transplant type, the market is segmented into allogeneic and autologous. Out of which, autologus is expected to hold a dominant position in the global hematopoietic stem cell transplantation (HSCT) market during the forecast period, and this is attributed to the  increasing use of autologous cell transplantation.
  • Based on indication, the market is segmented into acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), multiple myeloma (MM), and other disorders. Out of which, acute myeloid leukemia (AML) is expected to dominate the market over the forecast period, and this is attributed to increasing prevalence of AML.
  • Based on application, the market is segmented into bone marrow transplant (BMT), peripheral blood stem cells transplant (PBSCT), and cord blood transplant (CBT). Out of which, Bone Marrow Transplant (BMT), is expected to dominate the market over the forecast period and this is attributed to increasing prevalence of leukemia.
  • Based on end user, the market is segmented into hospitals, specialty clinics, and others. Out of which, the hospitals is expected to dominate the market over the forecast period, and this is attributed to increasing number of bone marrow transplantation procedures.
  • Based on region, the market is segmented into North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. Out of which, North America is expected to dominate the market over the forecast period, and this is attributed to increasing partnership and collaboration by key market players.

Among all the segmentation, the transplant type segment is expected to dominate the market over the forecast period, and this is attributed to increasing inorganic growth strategies such as acquisition by key market players to expand their product portfolio. For instance, in September 2021, Sanofi, a pharmaceutical company, announced the acquisitions of  Kadmon Holdings, Inc., a biopharmaceutical company that discovers, develops, and markets transformative therapies. The acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and immediately add Rezurock (belumosudil) to its transplant portfolio. Rezurock is a first-in-class treatment for chronic graft-versus-host disease (cGVHD) in adult and pediatric patients 12 years of age and older who have failed at least two prior lines of systemic therapy.

Hematopoietic Stem Cell Transplantation (HSCT) Market Report Coverage

Report Coverage Details
Base Year: 2022 Market Size in 2023: US$ 2.88 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 to 2030
Forecast Period 2023 to 2030 CAGR: 11.2% 2030 Value Projection: US$ 6.05 Bn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Transplant Type: Allogeneic, Autologous
  • By Indication: Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Hodgkin lymphoma (HL), Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Others
  • By Application: Bone Marrow Transplant (BMT), Peripheral Blood Stem Cells Transplant (PBSCT), Cord Blood Transplant (CBT)
  • By End User: Hospitals, Specialty Clinics, Others
Companies covered:

Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Inc., Talaris Therapeutics, Inc., Marker Therapeutics Inc., Stempeutics Research Pvt Ltd., CBR Systems Inc., Priothera Ltd., Eurobio Scientific Group, Otsuka America Pharmaceutical, Inc., Pfizer Inc., Sanofi, FUJIFILM Holdings Corporation
Growth Drivers:
  • Increasing prevalance of cancer
  • Increasing geriatric population 
  • Rising incidence of leukemia and lymphoma
Restraints & Challenges:
  • Side effects associated with hematopoietic stem cell transplantation (HSCT)
  • Strignet rules and regulation for hematopoietic stem cell transplantation (HSCT)

Global Hematopoietic Stem Cell Transplantation (HSCT) Market - Cross Sectional Analysis:

The increasing inorganic growth strategies, such as acquisitions by key market players to expand their product portfolio, are expected to drive market growth in North America region over the forecast period. For instance, in June 2021, Avalon Globocare Corp., a commercial-stage company, announced the acquisition of Hebei Senlang Biotechnology Co. Ltd., a cell therapy company, and developed a robust pipeline that includes 15 autologous and universal (“off-the-shelf”) CAR-T and CAR-γδT cell therapy candidates targeting hematologic malignancies and solid tumors.

Global Hematopoietic Stem Cell Transplantation (HSCT) Market : Key Developments

On June 19, 2023, Kindred Group plc, a company that offers online services, launched a new campaign with Matchis, the Dutch Centre for Stem Cell Donors, to generate more awareness for stem cell transplantation and the shortage of donors.

On January 23, 2023, Researchers at Children's Hospital of Philadelphia (CHOP) developed a custom-built application to automate the determination of engraftment, a key outcome after hematopoietic stem cell transplant (HSCT). The application supersedes a tedious manual process and, at the same time, substantially improves the accuracy of reported hematopoietic cell transplant engraftments.

On January 4, 2023, Jasper Therapeutics, Inc., announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted orphan drug designation to briquilimab (formerly known as JSP191), a monoclonal antibody targeting the CD117 (stem cell factor) receptor, for conditioning treatment prior to HCT. Previously, the U.S. Food and Drug Administration granted orphan drug designation to briquilimab in HCT, as well as rare pediatric disease designation for the treatment of severe combined immunodeficiency (SCID).

In June 2022, Veloxis Pharmaceuticals, a specialty pharmaceutical company, announced the dosing of the first patient by its partner, Xenikos B.V., a privately held biotechnology company, in a pivotal Phase 3 clinical study [NCT04934670] designed to evaluate T-Guard versus ruxolitinib for the treatment of patients with Grade III or IV steroid-refractory acute graft-versus-host disease (SR-aGVHD) following allogeneic hematopoietic stem cell transplant (allo-HSCT). T-Guard is currently being developed by Xenikos B.V.

Global Hematopoietic Stem Cell Transplantation (HSCT) Market : Key Trends

  • Increasing inorganic growth strategies such as collaboration and license agreement: Increasing inorganic growth strategies such as collaboration and license agreements by key market players to expand their product portfolio are expected to drive market growth over the forecast period. For instance, in June 2021, Heartseed Inc., a manufacturer of cell therapies, and Novo Nordisk A/S, a healthcare company, announced that they had entered into a collaboration and license agreement for the development, manufacturing, and commercialization of Heartseed’s lead asset, HS-001. HS-001 is an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC), which is currently under development by Heartseed for the treatment of heart failure.

Global Hematopoietic Stem Cell Transplantation (HSCT) Market : Restraint

  • Stringent Rules and Regulation for Hematopoietic Stem Cell Transplantation (HSCT): Factors such as side effects associated with hematopoietic stem cell transplantation (HSCT) and stringnet rules and regulations for hematopoietic stem cell transplantation (HSCT) can hamper growth of the hematopoietic stem cell transplantation (HSCT) market over the forecast period. For instance, in January 2023, the Indian Council of Medical Research (ICMR), provide guidelines for umbilical cord blood banking. In India, the UCB banks are required to comply with the provisions specified under Part X-B and Part XII-D of Schedule F of the Drugs and Cosmetics Act 1940 and Rules 1945 (Amendments 2016). The Indian rules define umbilical cord blood as the whole blood, including hematopoietic progenitor cells collected from placental and/or umbilical cord blood vessels after the umbilical cord has been clamped.

The company operating in market should follows the rules and regulation during development process of product to maintain the quality of product

Global Hematopoietic Stem Cell Transplantation (HSCT) Market  - Key Players

Major players operating in the global hematopoietic stem cell transplantation (HSCT) market include Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Inc., Talaris Therapeutics, Inc., Marker Therapeutics Inc., Stempeutics Research Pvt Ltd., CBR Systems Inc., Priothera Ltd., Eurobio Scientific Group, Otsuka America Pharmaceutical, Inc., Pfizer Inc., Sanofi, FUJIFILM Holdings Corporation

Definition: Hematopoietic stem cell transplantation (HSCT) is a treatment for some types of cancer and other diseases. Stem cells can come from the blood or bone marrow. The Food and Drug Administration (FDA)Trusted Source has approved the use of stem cell transplants to treat multiple myeloma, leukemia, some lymphomas, and others. Hematopoietic stem cell transplantation (HSCT) is the curative option for many primary immune deficiency disorders (PID). Pediatric hematopoietic stem cell transplantation involves the infusion of blood stem cells into a patient to reconstitute the blood system.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Transplant Type
      • Market Snippet, By Indication
      • Market Snippet, By Application
      • Market Snippet, By End User
      • Market Snippet, By Region
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Recent Test Launches
    • Epidemiology
    • Merger, Acquisition, and Collaborations
    • Regulatory Scenario
    • Key Developments
    • PEST Analysis
  4. Global Hematopoietic Stem Cell Transplantation (HSCT) Market– COVID-19 Impact Analysis
    • Economic Impact
    • COVID-19 Epidemiology
    • Impact on Supply and Demand
  5. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Transplant Type, 2018- 2030, (US$ Bn)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018–2030
      • Segment Trends
    • Allogeneic
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
    • Autologous
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
  6. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Indication, 2018 – 2030, (US$ Bn)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018–2030
      • Segment Trends
    • Acute Myeloid Leukemia (AML)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
    • Acute Lymphoblastic Leukemia (ALL)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
    • Hodgkin lymphoma (HL)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
    • Non-Hodgkin Lymphoma (NHL)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
    • Multiple Myeloma (MM)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
  7. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Application, 2018 – 2030, (US$ Bn)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018–2030
      • Segment Trends
    • Bone Marrow Transplant (BMT)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
    • Peripheral Blood Stem Cells Transplant (PBSCT)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
    • Cord Blood Transplant (CBT)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
  8. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By End User, 2018 – 2030, (US$ Bn)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018–2030
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
    • Specialty Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
  9. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Region, 2018 – 2030, (US$ Bn)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018–2030
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast,Y-o-Y Growth and By Transplant Type, 2018 –2030, (US$ Bn)
      • Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 –2030, (US$ Bn)
      • Market Size and Forecast,Y-o-Y Growth and By Application, 2018–2030, (US$ Bn)
      • Market Size and Forecast,Y-o-Y Growth and By End User, 2018–2030, (US$ Bn)
      • Market Size and Forecast, By Country, Y-o-Y Growth and By Country,  2018 –2030, (US$ Bn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast,Y-o-Y Growth and By Transplant Type, 2018 –2030, (US$ Bn)
      • Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 –2030, (US$ Bn)
      • Market Size and Forecast,Y-o-Y Growth and By Application, 2018–2030, (US$ Bn)
      • Market Size and Forecast,Y-o-Y Growth and By End User, 2018–2030, (US$ Bn)
      • Market Size and Forecast, By Country, Y-o-Y Growth and By Country,  2018 –2030, (US$ Bn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast,Y-o-Y Growth and By Transplant Type, 2018 –2030, (US$ Bn)
      • Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 –2030, (US$ Bn)
      • Market Size and Forecast,Y-o-Y Growth and By Application, 2018–2030, (US$ Bn)
      • Market Size and Forecast,Y-o-Y Growth and By End User, 2018–2030, (US$ Bn)
      • Market Size and Forecast, By Country, Y-o-Y Growth and By Country,  2018 –2030, (US$ Bn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast,Y-o-Y Growth and By Transplant Type, 2018 –2030, (US$ Bn)
      • Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 –2030, (US$ Bn)
      • Market Size and Forecast,Y-o-Y Growth and By Application, 2018–2030, (US$ Bn)
      • Market Size and Forecast,Y-o-Y Growth and By End User, 2018–2030, (US$ Bn)
      • Market Size and Forecast, By Country, Y-o-Y Growth and By Country,  2018 –2030, (US$ Bn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast,Y-o-Y Growth and By Transplant Type, 2018 –2030, (US$ Bn)
      • Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 –2030, (US$ Bn)
      • Market Size and Forecast,Y-o-Y Growth and By Application, 2018–2030, (US$ Bn)
      • Market Size and Forecast,Y-o-Y Growth and By End User, 2018–2030, (US$ Bn)
      • Market Size and Forecast, By Country, Y-o-Y Growth and By Country,  2018 –2030, (US$ Bn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast,Y-o-Y Growth and By Transplant Type, 2018 –2030, (US$ Bn)
      • Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 –2030, (US$ Bn)
      • Market Size and Forecast,Y-o-Y Growth and By Application, 2018–2030, (US$ Bn)
      • Market Size and Forecast,Y-o-Y Growth and By End User, 2018–2030, (US$ Bn)
      • Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region,  2018 –2030, (US$ Bn)
        • North Africa
        • Central Africa
        • South Africa
  10. Competitive Landscape
    • Company Profiles
      • Pluristem Therapeutics Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • CellGenix GmbH
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Regen Biopharma Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Lonza Group
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Kiadis Pharma
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Taiga Biotechnologies, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Takeda Pharmaceutical Company Limited
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Escape Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Bluebird Bio,Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Talaris Therapeutics, Inc.,
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Marker Therapeutics Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Stempeutics Research Pvt Ltd.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • CBR Systems Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Priothera Ltd.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Eurobio Scientific Group
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Otsuka America Pharmaceutical, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Sanofi
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • FUJIFILM Holdings Corporation
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
  11. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 38 market data tables and 33 figures on “Global Hematopoietic Stem Cell Transplantation (HSCT) Market” – Global forecast to 2030

Detailed Segmentation:

  • Global Hematopoietic Stem Cell Transplantation (HSCT) Market , By Transplant Type:
    • Allogeneic
    • Autologous
  • Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Indication:
    • Acute Myeloid Leukemia (AML)
    • Acute Lymphoblastic Leukemia (ALL)
    • Hodgkin lymphoma (HL)
    • Non-Hodgkin Lymphoma (NHL)
    • Multiple Myeloma (MM)
    • Others
  • Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Application:
    • Bone Marrow Transplant (BMT)
    • Peripheral Blood Stem Cells Transplant (PBSCT)
    • Cord Blood Transplant (CBT)
  • Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By End User:
    • Hospitals
    • Specialty Clinics
    • Others
  • Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Region:
    • North America
      • By Transplant Type:
        • Allogeneic
        • Autologous
      • By Indication
        • Acute Myeloid Leukemia (AML)
        • Acute Lymphoblastic Leukemia (ALL)
        • Hodgkin lymphoma (HL)
        • Non-Hodgkin Lymphoma (NHL)
        • Multiple Myeloma (MM)
        • Others
      • By Application
        • Bone Marrow Transplant (BMT)
        • Peripheral Blood Stem Cells Transplant (PBSCT)
        • Cord Blood Transplant (CBT)
      • By End User
        • Hospitals
        • Specialty Clinics
        • Others
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Transplant Type:
        • Allogeneic
        • Autologous
      • By Indication
        • Acute Myeloid Leukemia (AML)
        • Acute Lymphoblastic Leukemia (ALL)
        • Hodgkin lymphoma (HL)
        • Non-Hodgkin Lymphoma (NHL)
        • Multiple Myeloma (MM)
        • Others
      • By Application
        • Bone Marrow Transplant (BMT)
        • Peripheral Blood Stem Cells Transplant (PBSCT)
        • Cord Blood Transplant (CBT)
      • By End User
        • Hospitals
        • Specialty Clinics
        • Others
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Transplant Type:
        • Allogeneic
        • Autologous
      • By Indication
        • Acute Myeloid Leukemia (AML)
        • Acute Lymphoblastic Leukemia (ALL)
        • Hodgkin lymphoma (HL)
        • Non-Hodgkin Lymphoma (NHL)
        • Multiple Myeloma (MM)
        • Others
      • By Application
        • Bone Marrow Transplant (BMT)
        • Peripheral Blood Stem Cells Transplant (PBSCT)
        • Cord Blood Transplant (CBT)
      • By End User
        • Hospitals
        • Specialty Clinics
        • Others
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Transplant Type:
        • Allogeneic
        • Autologous
      • By Indication
        • Acute Myeloid Leukemia (AML)
        • Acute Lymphoblastic Leukemia (ALL)
        • Hodgkin lymphoma (HL)
        • Non-Hodgkin Lymphoma (NHL)
        • Multiple Myeloma (MM)
        • Others
      • By Application
        • Bone Marrow Transplant (BMT)
        • Peripheral Blood Stem Cells Transplant (PBSCT)
        • Cord Blood Transplant (CBT)
      • By End User
        • Hospitals
        • Specialty Clinics
        • Others
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Transplant Type:
        • Allogeneic
        • Autologous
      • By Indication
        • Acute Myeloid Leukemia (AML)
        • Acute Lymphoblastic Leukemia (ALL)
        • Hodgkin lymphoma (HL)
        • Non-Hodgkin Lymphoma (NHL)
        • Multiple Myeloma (MM)
        • Others
      • By Application
        • Bone Marrow Transplant (BMT)
        • Peripheral Blood Stem Cells Transplant (PBSCT)
        • Cord Blood Transplant (CBT)
      • By End User
        • Hospitals
        • Specialty Clinics
        • Others
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Transplant Type:
        • Allogeneic
        • Autologous
      • By Indication
        • Acute Myeloid Leukemia (AML)
        • Acute Lymphoblastic Leukemia (ALL)
        • Hodgkin lymphoma (HL)
        • Non-Hodgkin Lymphoma (NHL)
        • Multiple Myeloma (MM)
        • Others
      • By Application
        • Bone Marrow Transplant (BMT)
        • Peripheral Blood Stem Cells Transplant (PBSCT)
        • Cord Blood Transplant (CBT)
      • By End User
        • Hospitals
        • Specialty Clinics
        • Others
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global hematopoietic stem cell transplantation (HSCT) market during the forecast period (2023-2030)?

The global hematopoietic stem cell transplantation (HSCT) market  is estimated to be valued at US$ 2.88 Billion in 2023 and is expected to exhibit a CAGR of 11.2% between 2023 and 2030.

What are the major factors driving the market’s growth?

Increasing prevalance of cancer, increasing geriatric population and  rising incidence of leukemia and lymphoma are expected to drive the global hematopoietic stem cell transplantation (HSCT) market’s  growth.

Which is the leading transplant type segment in the market ?

Autologus transplant type is the leading transplnat type segment in the market.

What are the key factors hampering the growth of the market ?

Factors such as side effects associated with hematopoietic stem cell transplantation (HSCT) and strict rules and regulations for hematopoietic stem cell transplantation (HSCT) are expected to hinder the market  over the forecast period.

Which are the major players operating in the market ?

Major players operating in the market  are Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Inc., Talaris Therapeutics, Inc., Marker Therapeutics Inc., Stempeutics Research Pvt Ltd., CBR Systems Inc., Priothera Ltd., Eurobio Scientific Group, Otsuka America Pharmaceutical, Inc., Pfizer Inc., Sanofi, and FUJIFILM Holdings Corporation
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.
Buy Now with Special Discount
Customize Now